Short Interest in Burning Rock Biotech Limited (NASDAQ:BNR) Decreases By 30.2%

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 84,000 shares, a decrease of 30.2% from the October 15th total of 120,300 shares. Currently, 1.0% of the shares of the company are sold short. Based on an average trading volume of 30,600 shares, the days-to-cover ratio is currently 2.7 days.

Burning Rock Biotech Stock Performance

Shares of NASDAQ:BNR traded up $0.05 during trading hours on Friday, hitting $3.75. The stock had a trading volume of 10,434 shares, compared to its average volume of 13,661. The stock’s fifty day simple moving average is $3.35 and its 200 day simple moving average is $5.67. Burning Rock Biotech has a 1-year low of $2.62 and a 1-year high of $9.99. The firm has a market capitalization of $38.40 million, a price-to-earnings ratio of -0.71 and a beta of 0.14.

Burning Rock Biotech (NASDAQ:BNR) last announced its quarterly earnings results on Thursday, August 22nd. The company reported ($0.14) EPS for the quarter. Burning Rock Biotech had a negative net margin of 111.25% and a negative return on equity of 74.96%. The firm had revenue of $18.65 million during the quarter.

Institutional Investors Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC acquired a new stake in Burning Rock Biotech Limited (NASDAQ:BNR) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned approximately 0.10% of Burning Rock Biotech at the end of the most recent reporting period. Institutional investors own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.